Posted by Michael Wonder on 06 Apr 2022
Dialectic Therapeutics announces DT2216 has received fast track designation from the FDA for adult patients with relapsed or refractory peripheral and cutaneous T-cell lymphoma
5 April 2022 - Dialectic Therapeutics today announced that the U.S. FDA has granted fast track designation to DT2216 for adult patients with relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
DT2216 is Dialectic's first generation compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology platform.
